Rare diseases
Investigational molecules
Locations
Recruiting trials first
1 clinical trial in this condition
FranceIn short
Diagnosing squamous cell carcinoma of the vagina requires several steps, from recognizing symptoms to confirming the presence of cancer through medical tests. Early detection can improve outcomes, but this cancer often develops slowly without causing noticeable signs in its early stages, making regular check-ups particularly important for women at higher risk.
Not everyone needs to be actively concerned about vaginal cancer, but certain groups of women should be more vigilant about seeking medical evaluation. If you are experiencing unusual symptoms such as vaginal bleeding that is not related to your menstrual cycle, particularly if you have already gone through menopause and no longer have periods, it is important to see a doctor. Bleeding after sexual intercourse is another warning sign that should not be ignored.
Sometimes, you might notice a lump or mass in the vaginal area, which can cause discomfort or pain during sex. Pain in the pelvic region, difficulty or pain when urinating, or even constipation can also be signs that something is not right and warrants a medical visit. However, it is worth noting that in many cases, squamous cell carcinoma of the vagina does not cause any symptoms in its earliest stages. This is why routine screenings and pelvic exams are so valuable, especially for women who fall into higher-risk groups.
Women over the age of 60 should be especially attentive, as the average age of diagnosis for this cancer is around 60 years old. If you have a history of cervical cancer, have been diagnosed with abnormal cervical cells, or have tested positive for human papillomavirus (HPV), you should discuss regular vaginal health checks with your healthcare provider. Women who smoke, have had multiple sexual partners, or began sexual activity at a young age are also at increased risk. Those who have been treated for cervical or vulvar cancer or dysplasia should continue with routine follow-up examinations, as they have a higher chance of developing vaginal cancer.
The process of diagnosing squamous cell carcinoma of the vagina typically begins with a thorough medical history and physical examination. Your doctor will ask about any symptoms you are experiencing, your sexual history, smoking habits, past illnesses, and any family history of cancer. This conversation helps the doctor understand your risk factors and determine which tests are most appropriate.
The most fundamental step in diagnosing vaginal cancer is a pelvic exam. During this examination, the doctor uses an instrument called a speculum to gently open the vaginal canal. This allows the doctor to carefully inspect the vagina and cervix for any irregularities, such as unusual growths, lumps, sores, or areas of abnormal tissue. The pelvic exam also includes a bimanual examination, where the doctor inserts two gloved fingers into the vagina while pressing on the abdomen with the other hand. This helps the doctor feel the size and shape of the uterus, ovaries, and other pelvic organs to detect any masses or abnormalities.
In some cases, the doctor may also perform a rectovaginal exam, which involves inserting one finger into the vagina and another into the rectum. This exam allows the doctor to check whether the cancer has spread to the rectal area or other nearby tissues. While these exams can feel uncomfortable, they are quick and provide valuable information about the health of your reproductive organs.
A Pap smear (also called a Papanicolaou test) is another important tool for detecting vaginal abnormalities. During a Pap test, the doctor uses a small brush or swab to collect cells from the surface of the vagina and cervix. These cells are then sent to a laboratory, where they are examined under a microscope to look for any changes that might indicate cancer or precancerous conditions. Although the Pap test is primarily used to screen for cervical cancer, it can also help identify abnormal vaginal cells.
If the pelvic exam or Pap test reveals something suspicious, the doctor may recommend a colposcopy. A colposcopy is a more detailed examination of the vagina and cervix using a special magnifying instrument called a colposcope. This device allows the doctor to see the vaginal tissues more clearly and identify areas that might need further investigation. The colposcope does not enter the body; it remains outside while providing a magnified view. If abnormal areas are found during colposcopy, the doctor can take samples of tissue for further testing.
The definitive way to diagnose squamous cell carcinoma of the vagina is through a biopsy. A biopsy involves removing a small sample of tissue from the vagina so it can be examined under a microscope by a specialist called a pathologist. The biopsy can often be done in the doctor's office, with local anesthesia used to numb the area and minimize discomfort. The doctor may use a small blade or a circular cutting tool to remove the tissue sample. In some cases, the biopsy is performed in an operating room under deeper sedation or general anesthesia, especially if a larger or more difficult-to-reach area needs to be sampled.
The tissue sample is sent to a laboratory, where the pathologist examines the cells to determine whether cancer is present and, if so, what type it is. To confirm that the cancer truly originated in the vagina, the doctor must also rule out the possibility that the cancer spread to the vagina from another part of the body, such as the cervix or uterus. This is important because treatment strategies differ depending on where the cancer first developed.
Once cancer is confirmed, additional tests are needed to determine how far it has spread. This process is called staging. Staging tests help doctors understand the extent of the cancer and plan the most effective treatment. A chest X-ray is often done to check whether the cancer has spread to the lungs. Computed tomography (CT) scans, magnetic resonance imaging (MRI), and positron emission tomography (PET) scans are imaging techniques that create detailed pictures of the inside of the body. These scans help doctors see if the cancer has spread to lymph nodes, the bladder, rectum, or distant organs such as the liver or bones.
Another test that may be used to evaluate the extent of cancer spread is vaginal cytology. This test examines cells from the vaginal lining to look for cancerous changes. It is similar to a Pap smear but focuses specifically on the vaginal tissues. In some cases, doctors may also perform additional examinations of the bladder or rectum using specialized instruments if they suspect the cancer has spread to these organs.
Clinical trials are research studies that test new treatments, diagnostic methods, or prevention strategies for diseases, including vaginal cancer. Participating in a clinical trial can give patients access to cutting-edge therapies that are not yet widely available. However, not everyone is eligible to participate in every trial. Each clinical trial has specific criteria, called inclusion and exclusion criteria, that determine who can and cannot join the study. These criteria are designed to ensure patient safety and to produce reliable, meaningful results from the research.
To determine whether a patient qualifies for a clinical trial, doctors must perform a series of diagnostic tests and assessments. These tests confirm the diagnosis, determine the stage and characteristics of the cancer, and assess the patient's overall health. The specific tests required depend on the goals and design of the clinical trial, but they often include many of the same diagnostic procedures used in standard clinical practice.
First, patients must have a confirmed diagnosis of squamous cell carcinoma of the vagina, typically through a biopsy. The biopsy not only confirms the presence of cancer but also provides information about the type and characteristics of the cancer cells. Some clinical trials may require additional tests on the biopsy sample, such as tests for specific genetic markers or proteins that can help predict how the cancer will respond to treatment.
Staging tests are also essential for clinical trial qualification. Most clinical trials are designed for patients at a specific stage of disease. For example, a trial might be open only to patients with early-stage vaginal cancer, or it might focus on those with advanced or recurrent disease. To determine a patient's eligibility, doctors use imaging tests such as chest X-rays, CT scans, MRI scans, and PET scans to assess the size of the tumor and whether the cancer has spread to lymph nodes or other organs.
In addition to cancer-specific tests, clinical trials often require assessments of the patient's overall health and organ function. Blood tests are commonly performed to check the function of the liver, kidneys, and bone marrow. These tests help ensure that the patient is healthy enough to tolerate the experimental treatment being studied. For example, some treatments can affect the kidneys or liver, so doctors need to know that these organs are functioning well before the patient can safely participate.
Some clinical trials also require testing for human papillomavirus (HPV), as the presence of this virus can influence the behavior of the cancer and its response to treatment. HPV testing is typically done on a sample of vaginal tissue or cells. If a trial is studying a treatment that targets HPV-related cancers, only patients with HPV-positive tumors may be eligible.
Other tests that might be required for clinical trial qualification include electrocardiograms (ECGs) to assess heart function, especially if the treatment being studied has potential effects on the heart. Performance status assessments, which evaluate how well a patient can perform daily activities, are also commonly used to determine eligibility. These assessments help researchers understand whether a patient is strong enough to participate in the trial and to tolerate the study treatment.
It is important to understand that even if a patient meets all the medical criteria, there may be other factors that affect eligibility, such as age, previous treatments, or the presence of other medical conditions. Each clinical trial has its own unique set of requirements, so it is essential for patients and their doctors to carefully review the trial's eligibility criteria. If you are interested in participating in a clinical trial, your healthcare team can help you find trials that may be appropriate for your situation and guide you through the qualification process.
The prognosis for squamous cell carcinoma of the vagina depends on several factors, including the stage of the cancer at diagnosis, the location of the tumor within the vagina, and the characteristics of the cancer cells. Women diagnosed at an early stage, when the cancer is still confined to the vaginal wall, generally have a better outlook than those diagnosed with more advanced disease that has spread to nearby organs or distant sites. The type of treatment received also influences outcomes, as does the patient's overall health and fitness level. Younger, healthier women often respond better to treatment and may have better chances of recovery. Squamous cell carcinoma of the vagina tends to grow slowly, which can be an advantage if it is caught early. However, because it often causes no symptoms in its early stages, many women are not diagnosed until the cancer has progressed to a more advanced stage, which can make treatment more challenging.
Survival rates for vaginal cancer vary depending on the stage at diagnosis. According to American statistics, women with localized vaginal cancer (cancer that is only in the vaginal wall) have a five-year survival rate of around 70%, meaning that about 70 out of 100 women with this stage of cancer are still alive five years after diagnosis. For regional disease, where the cancer has spread to nearby lymph nodes or tissues, the five-year survival rate is more than 55%. Women diagnosed with distant disease, where the cancer has spread to other parts of the body such as the lungs, liver, or bones, have a five-year survival rate of around 25%. It is important to remember that these statistics are averages based on large groups of people and may not reflect individual outcomes. Many factors can influence survival, and advances in treatment continue to improve the outlook for women with vaginal cancer.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
